Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Amicus Therapeutics stock price, quote, forecast and news

FOLD
US03152W1099
A0MSMZ

Price

11.76
Today +/-
+0.05
Today %
+0.51 %
P

Amicus Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Amicus Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Amicus Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Amicus Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Amicus Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Amicus Therapeutics Stock Price History

DateAmicus Therapeutics Price
8/23/202411.76 undefined
8/22/202411.70 undefined
8/21/202412.09 undefined
8/20/202411.92 undefined
8/19/202411.89 undefined
8/16/202411.47 undefined
8/15/202411.45 undefined
8/14/202411.50 undefined
8/13/202411.72 undefined
8/12/202411.58 undefined
8/9/202411.48 undefined
8/8/202411.32 undefined
8/7/202410.00 undefined
8/6/20249.94 undefined
8/5/20249.55 undefined
8/2/202410.08 undefined
8/1/202410.20 undefined
7/31/202410.31 undefined
7/30/202410.08 undefined
7/29/202410.11 undefined
7/26/202410.18 undefined

Amicus Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amicus Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amicus Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amicus Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amicus Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amicus Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amicus Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amicus Therapeutics’s growth potential.

Amicus Therapeutics Revenue, EBIT and net profit per share

DateAmicus Therapeutics RevenueAmicus Therapeutics EBITAmicus Therapeutics Net Income
2030e1.28 B undefined829.46 M undefined664.67 M undefined
2029e1.42 B undefined749.43 M undefined954.71 M undefined
2028e1.3 B undefined670.04 M undefined669.2 M undefined
2027e1.08 B undefined482.73 M undefined472.82 M undefined
2026e827.88 M undefined269.6 M undefined190.77 M undefined
2025e652.93 M undefined108.58 M undefined65.33 M undefined
2024e527.36 M undefined-17.47 M undefined-56.73 M undefined
2023399.36 M undefined-76.08 M undefined-151.58 M undefined
2022329.2 M undefined-205.5 M undefined-236.6 M undefined
2021305.5 M undefined-206.4 M undefined-250.5 M undefined
2020260.9 M undefined-247 M undefined-276.9 M undefined
2019182.2 M undefined-304.1 M undefined-356.4 M undefined
201891.2 M undefined-328.8 M undefined-349 M undefined
201736.9 M undefined23.4 M undefined-284 M undefined
20165 M undefined-181.8 M undefined-200 M undefined
20150 undefined-130.4 M undefined-132.1 M undefined
20141.2 M undefined-68.8 M undefined-68.9 M undefined
2013400,000 undefined-61.7 M undefined-59.6 M undefined
201218.4 M undefined-52.9 M undefined-48.8 M undefined
201121.4 M undefined-50.9 M undefined-44.4 M undefined
2010900,000 undefined-55.8 M undefined-54.9 M undefined
200964.4 M undefined-5.9 M undefined-6.6 M undefined
200815 M undefined-44 M undefined-39.4 M undefined
20071.8 M undefined-45.8 M undefined-41.5 M undefined
20060 undefined-46.9 M undefined-65.9 M undefined
20050 undefined-20.8 M undefined-20.1 M undefined
20040 undefined-8.5 M undefined-8.9 M undefined

Amicus Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000.020.0600.020.020000.010.040.090.180.260.310.330.40.530.650.831.081.31.421.28
-----1,400.00326.67---14.29----620.00152.78100.0042.8617.317.8721.2832.0823.7226.8430.5920.289.55-9.77
-------------80.0083.3383.5287.9188.0888.8588.1590.73-------
0000000000000430761602292712903620000000
-5-8-20-46-45-44-5-55-50-52-61-68-130-18123-328-304-247-206-205-76-17108269482670749829
-----4,500.00-293.33-7.81--238.10-288.89--6,800.00--3,620.0063.89-360.44-167.03-95.00-67.54-62.31-19.05-3.2316.5632.5344.6351.5852.6464.56
-6-8-20-65-41-39-6-54-44-48-59-68-132-200-284-349-356-276-250-236-151-5665190472669954664
-33.33150.00225.00-36.92-4.88-84.62800.00-18.529.0922.9215.2594.1251.5242.0022.892.01-22.47-9.42-5.60-36.02-62.91-216.07192.31148.4241.7442.60-30.40
22.222.222.222.213.222.522.627.734.645.651.374.4109.9134.4153.4185.8240.4258.9271.4289.1295.160000000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Amicus Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Amicus Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
4.324.454.7161.5121.178.2107.455.799.182151.7214330.4358.6504.2452.7483.3482.5293.6286.2
000000053.21.1001.39.52233.346.952.766.287.63
00000000000000000000
0000000000003.44.68.41419.626.823.859.7
0.20.40.31.52.52.32.25.92.35.22.92.6519.316.62029.734.840.249.53
4.524.855163123.680.5109.666.6104.688.3154.6216.6340.1392551.2520579.5596.8423.8483.06
0.53.34.43.84.94.42.62.454.12.86.29.89.111.48167.263.160.357.98
000000000017.5000000000
00000000000000000000
0000000002323486.7486.723232323232320.49
00000000011.611.6197.8197.8197.8197.8197.8197.8197.8197.8197.8
00.50.30.30.30.50.30.70.40.60.51.12.55.26.728.319.124.419.218.55
0.53.84.74.15.24.92.93.15.439.355.4691.8696.8235.1238.9330.1307.1308.3300.3294.82
0.010.030.060.170.130.090.110.070.110.130.210.911.040.630.790.850.890.910.720.78
2060.5124.20.30.30.30.40.40.60.711.31.51.71.92.62.72.82.82.92
000.010.230.230.240.290.30.390.420.570.921.121.41.742.232.312.62.662.84
-17.3-37.3-83.7-124.8-164.2-170.8-225.7-270.1-318.9-378.5-447.4-570.8-763.5-1,047.5-1,399.2-1,756.2-2,033.1-2,295.8-2,532.4-2,684
-0.1-2.500000000001.9-1.70.52.88.45.3-125.43
00040050000000-100-100100-400-4000-200-300-100-188
4.224.746.6103.37171.864.929.669.245.8122.2347.9360.2352.9342.9476.4286.4307.4123160.17
0.60.91.20.523.822.62.12.15.916.512.916.444.451.417.121.515.415.12
0.21.47.79.96.85.86.37.16.7810.515.727.837.236.268.988.495.288.7129.76
0003.83.706.68.500041.47016.25.58.624.229.334.922.81
00000000000000000000
0.20.31.31.50.91.61.310.40.33.800.30.3000000
12.610.215.713.411.216.219.29.210.420.273.611170.186.1128.9129.7146139167.69
00.72.31.20.32.3100.314.210.50154.5164.2321.7149.5389.3389.4392387.86
0000000009.29.2176.2173.86.56.55.14.94.94.90
00.70.646.844030.420.931.34847.9310.7237.533.532.790.476.357.565.262.16
01.42.94844.32.331.420.931.671.467.6486.9565.8204.2360.9245470.5451.8462.1450.02
1413.163.757.713.547.640.140.881.887.8560.5676.8274.3447373.9600.2597.8601.1617.71
0.010.030.060.170.130.090.110.070.110.130.210.911.040.630.790.850.890.910.720.78
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Amicus Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Amicus Therapeutics's financial health and stability.

Assets

Amicus Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Amicus Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Amicus Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Amicus Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-6-8-19-46-41-39-6-54-44-48-59-68-132-200-284-349-356-276-250-236-151
000011221111133448657
0000000000000-3-1670-1000-4
1-10650-5-4631-12749141-24-411-32-28-39-47
1004412151314111312256628178135116128181213
00000000000102771624303436
00000000000000000102018
-3-9-18-3315-36-43-13-49-33-45-51-100-150-213-299-250-233-202-166-69
-10-3-20-2-10-1-400-4-5-4-6-20-3-3-3-7
-1-4-16-26-752131-1946-3926-107-145-4-171-12195-13789298
0-4-13-24-742433-1947-3526-106-1401-166-114115-108296105
000000000000000000000
3100-1-12-1-10140341920146023000-20
012406392004508115139258100259307201422294103
313416691-124308129139290272247450217262212-761
001300000000-2-19-11-216-10-16-11-20
000000000000000000000
-106532-16-810-389-1945117-13631631983-9696
-4.97-9.46-21.16-35.9214.52-39.53-45.18-14.36-50.84-38.06-46.49-51.91-104.96-156.1-218.23-306.27-270.43-236.52-206.37-170.35-76.53
000000000000000000000

Amicus Therapeutics stock margins

The Amicus Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amicus Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amicus Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amicus Therapeutics's sales revenue. A higher gross margin percentage indicates that the Amicus Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amicus Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amicus Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amicus Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amicus Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amicus Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amicus Therapeutics Margin History

Amicus Therapeutics Gross marginAmicus Therapeutics Profit marginAmicus Therapeutics EBIT marginAmicus Therapeutics Profit margin
2030e90.65 %64.55 %51.73 %
2029e90.65 %52.67 %67.09 %
2028e90.65 %51.58 %51.52 %
2027e90.65 %44.7 %43.78 %
2026e90.65 %32.57 %23.04 %
2025e90.65 %16.63 %10.01 %
2024e90.65 %-3.31 %-10.76 %
202390.65 %-19.05 %-37.96 %
202288.27 %-62.42 %-71.87 %
202188.71 %-67.56 %-82 %
202088.08 %-94.67 %-106.13 %
201987.98 %-166.9 %-195.61 %
201884.21 %-360.53 %-382.68 %
201783.2 %63.41 %-769.65 %
201682 %-3,636 %-4,000 %
201590.65 %0 %0 %
201490.65 %-5,733.33 %-5,741.67 %
201390.65 %-15,425 %-14,900 %
201290.65 %-287.5 %-265.22 %
201190.65 %-237.85 %-207.48 %
201090.65 %-6,200 %-6,100 %
200990.65 %-9.16 %-10.25 %
200890.65 %-293.33 %-262.67 %
200790.65 %-2,544.44 %-2,305.56 %
200690.65 %0 %0 %
200590.65 %0 %0 %
200490.65 %0 %0 %

Amicus Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Amicus Therapeutics earnings per share therefore indicates how much revenue Amicus Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amicus Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amicus Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amicus Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amicus Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amicus Therapeutics Revenue, EBIT and net profit per share

DateAmicus Therapeutics Sales per ShareAmicus Therapeutics EBIT per shareAmicus Therapeutics Earnings per Share
2030e4.34 undefined0 undefined2.24 undefined
2029e4.8 undefined0 undefined3.22 undefined
2028e4.39 undefined0 undefined2.26 undefined
2027e3.65 undefined0 undefined1.6 undefined
2026e2.8 undefined0 undefined0.64 undefined
2025e2.2 undefined0 undefined0.22 undefined
2024e1.78 undefined0 undefined-0.19 undefined
20231.35 undefined-0.26 undefined-0.51 undefined
20221.14 undefined-0.71 undefined-0.82 undefined
20211.13 undefined-0.76 undefined-0.92 undefined
20201.01 undefined-0.95 undefined-1.07 undefined
20190.76 undefined-1.26 undefined-1.48 undefined
20180.49 undefined-1.77 undefined-1.88 undefined
20170.24 undefined0.15 undefined-1.85 undefined
20160.04 undefined-1.35 undefined-1.49 undefined
20150 undefined-1.19 undefined-1.2 undefined
20140.02 undefined-0.92 undefined-0.93 undefined
20130.01 undefined-1.2 undefined-1.16 undefined
20120.4 undefined-1.16 undefined-1.07 undefined
20110.62 undefined-1.47 undefined-1.28 undefined
20100.03 undefined-2.01 undefined-1.98 undefined
20092.85 undefined-0.26 undefined-0.29 undefined
20080.67 undefined-1.96 undefined-1.75 undefined
20070.14 undefined-3.47 undefined-3.14 undefined
20060 undefined-2.11 undefined-2.97 undefined
20050 undefined-0.94 undefined-0.91 undefined
20040 undefined-0.38 undefined-0.4 undefined

Amicus Therapeutics business model

Amicus Therapeutics Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases. The company was founded in 2002 and is headquartered in Cranbury, New Jersey. Amicus Therapeutics is one of the most popular companies on Eulerpool.com.

Amicus Therapeutics SWOT Analysis

Strengths

Amicus Therapeutics Inc has a strong pipeline of innovative therapies in development, which provides potential for future revenue growth. The company's focus on rare and orphan diseases allows them to target niche markets with high unmet medical needs. Amicus also benefits from strategic partnerships and collaborations with leading pharmaceutical companies, enabling access to resources and expertise.

Weaknesses

One of the key weaknesses of Amicus Therapeutics Inc is its heavy dependence on a few product candidates for potential commercial success. The company faces the risk of clinical trial failures or regulatory setbacks, which could lead to significant delays or even complete termination of its product development programs. Additionally, Amicus may face challenges in scaling up manufacturing capabilities to meet potential market demand.

Opportunities

There are several opportunities available to Amicus Therapeutics Inc. The increasing prevalence of rare diseases and the growing importance of personalized medicine present potential markets for their targeted therapies. The company can also explore expansion into geographies with limited treatment options for rare diseases. Furthermore, advancements in gene therapy and precision medicine open doors for potential collaborations and partnerships.

Threats

Amicus Therapeutics Inc faces certain threats in its industry. Competition from well-established pharmaceutical companies and emerging biotech firms poses a challenge in capturing market share. Additionally, regulatory uncertainties and the possibility of changes in healthcare policies may impact the reimbursement landscape for Amicus' therapies. The company must also remain vigilant against potential intellectual property infringements.

Amicus Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Amicus Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Amicus Therapeutics shares outstanding

The number of shares was Amicus Therapeutics in 2023 — This indicates how many shares 295.165 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amicus Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amicus Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amicus Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amicus Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Amicus Therapeutics.

Amicus Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.06 -0.05  (11.66 %)2024 Q2
3/31/2024-0.07 -0.16  (-139.16 %)2024 Q1
12/31/2023-0.06 -0.11  (-83.03 %)2023 Q4
9/30/2023-0.08 -0.07  (9.21 %)2023 Q3
6/30/2023-0.13 -0.15  (-19.24 %)2023 Q2
3/31/2023-0.15 -0.18  (-20.32 %)2023 Q1
12/31/2022-0.13 -0.19  (-47.4 %)2022 Q4
9/30/2022-0.19 -0.12  (36.88 %)2022 Q3
6/30/2022-0.22 -0.21  (5.11 %)2022 Q2
3/31/2022-0.26 -0.3  (-15.34 %)2022 Q1
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Amicus Therapeutics stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

43

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees57
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Amicus Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.61 % The Vanguard Group, Inc.28,450,0701,360,61312/31/2023
9.47 % Perceptive Advisors LLC28,057,456364,53912/31/2023
9.25 % Avoro Capital Advisors LLC27,400,000012/31/2023
6.97 % BlackRock Institutional Trust Company, N.A.20,651,1631,971,28112/31/2023
5.13 % Wellington Management Company, LLP15,190,0247,666,33512/31/2023
5.01 % Redmile Group, LLC14,828,321-2,116,30012/31/2023
4.44 % State Street Global Advisors (US)13,163,0851,790,64912/31/2023
3.94 % JP Morgan Asset Management11,670,8834,804,62312/31/2023
3.93 % William Blair Investment Management, LLC11,647,0261,270,26312/31/2023
3.88 % Janus Henderson Investors11,507,129-3,426,89212/31/2023
1
2
3
4
5
...
10

Amicus Therapeutics Executives and Management Board

Mr. John Crowley56
Amicus Therapeutics Executive Chairman of the Board (since 2004)
Compensation 10 M
Mr. Bradley Campbell47
Amicus Therapeutics President, Chief Executive Officer, Director (since 2007)
Compensation 9 M
Ms. Ellen Rosenberg60
Amicus Therapeutics Chief Legal Officer, Corporate Secretary
Compensation 3.67 M
Ms. Daphne Quimi57
Amicus Therapeutics Senior Vice President - Finance
Compensation 3.65 M
Dr. Jeffrey Castelli51
Amicus Therapeutics Chief Development Officer
Compensation 3.06 M
1
2
3
4

Most common questions regarding Amicus Therapeutics

What values and corporate philosophy does Amicus Therapeutics represent?

Amicus Therapeutics Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on delivering life-changing therapies, Amicus strives to improve the lives of individuals with rare and devastating diseases. The company is committed to advancing science, developing transformative medicines, and ensuring access to those therapies for patients in need. Amicus fosters a collaborative and compassionate approach, working closely with patient advocacy groups, healthcare professionals, and regulatory authorities to make a meaningful impact in the lives of the communities it serves.

In which countries and regions is Amicus Therapeutics primarily present?

Amicus Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Amicus Therapeutics achieved?

Amicus Therapeutics Inc has achieved significant milestones in its journey. Some notable accomplishments include the approval of Galafold, a breakthrough therapy for Fabry disease, by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company has made remarkable progress in developing innovative therapies for rare genetic diseases such as Pompe disease and other lysosomal storage disorders. Amicus Therapeutics Inc has successfully conducted clinical trials and obtained positive results, showcasing their commitment to advancing medical science and improving patients' lives. Their unwavering dedication has positioned them as a leading player in the biopharmaceutical industry.

What is the history and background of the company Amicus Therapeutics?

Amicus Therapeutics Inc is a biopharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2002, Amicus Therapeutics focuses on developing advanced therapies for rare and orphan diseases. The company's innovative approach is based on the principles of personalized medicine, utilizing breakthrough science and technology. Over the years, Amicus Therapeutics has established itself as a leader in the field, with a strong dedication to improving the lives of patients with devastating genetic diseases. Through its robust research and development efforts, Amicus Therapeutics has successfully advanced several potential treatments, striving to bring hope and transformative therapies to those in need.

Who are the main competitors of Amicus Therapeutics in the market?

The main competitors of Amicus Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Sanofi Genzyme.

In which industries is Amicus Therapeutics primarily active?

Amicus Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Amicus Therapeutics?

The business model of Amicus Therapeutics Inc. revolves around developing advanced therapies for rare and orphan diseases. The company focuses on utilizing its Chaperone-Advanced Replacement Therapy (CHART™) platform to deliver enzyme replacement therapies (ERTs) for individuals suffering from lysosomal storage disorders (LSDs). As a biopharmaceutical company, Amicus Therapeutics aims to address unmet medical needs through innovative drug research and development. By leveraging their expertise in protein misfolding and folding, Amicus Therapeutics aims to improve the lives of patients with genetic diseases.

What is the P/E ratio of Amicus Therapeutics 2024?

The Amicus Therapeutics P/E ratio is -61.18.

What is the P/S ratio of Amicus Therapeutics 2024?

The Amicus Therapeutics P/S ratio is 6.58.

What is the AlleAktien quality score of Amicus Therapeutics?

The AlleAktien quality score for Amicus Therapeutics is 4/10.

What is the revenue of Amicus Therapeutics 2024?

The expected Amicus Therapeutics revenue is 527.36 M USD.

How high is the profit of Amicus Therapeutics 2024?

The expected Amicus Therapeutics profit is -56.73 M USD.

What is the business model of Amicus Therapeutics

Amicus Therapeutics Inc (Nasdaq: FOLD) aims to develop and manufacture novel therapies for people with rare and severe diseases. The biotechnology company, based in Cranbury, New Jersey, USA, focuses on researching and developing drugs that aim to influence the natural metabolism of proteins in the body to treat diseases caused by mutations in genes. The business model of Amicus Therapeutics is based on the discovery and development of therapies specialized in treating rare and severe diseases. The company works closely with patients and their families to gain a better understanding of the needs and challenges of these patient groups. Amicus utilizes a proprietary technology platform called Chaperon-Advanced Replacement Therapy (CHART), which allows for the treatment of Ectopic Glycosylation Disorders (EGS) by replacing faulty proteins produced by gene mutations with functional and stable therapeutics. Amicus Therapeutics specializes in the following three areas: 1. Fabry disease: A rare lysosomal metabolic disorder where the Alpha-Galactosidase-A enzyme is not produced normally due to mutations in the GLA gene. Amicus has developed Galafold, the first oral medication for treating Fabry disease, which aims to stabilize the faulty protein. 2. Pompe disease: A lysosomal storage disease characterized by a deficiency of enzymes that help in breaking down glycogen. This results in an accumulation of glycogen in various tissues and organs. Amicus has developed ATB200/AT2221, a combined therapy of enzyme replacement therapy and chaperone therapy aimed at correcting the enzyme deficiency caused by mutation. 3. Phenylketonuria (PKU): A metabolic disorder where an individual lacks the ability to metabolize phenylalanine. This leads to an accumulation of phenylalanine in the body, which can cause impairments to the central nervous system. Amicus has a pipeline of therapeutics in development for treating PKU, including a chaperone platform and an enzyme replacement therapy. Amicus Therapeutics collaborates closely with medical centers, patient organizations, and research institutions to develop innovative therapies for rare and severe diseases. The company is committed to enhancing the effectiveness and safety of medications, helping to improve the quality of life for affected individuals. By focusing on rare and severe diseases, Amicus Therapeutics can serve a niche and position itself as an innovator in the biotechnology industry. Overall, Amicus Therapeutics' business model has the potential to achieve significant medical advancements while also being profitable. The company is well-positioned to continue developing innovative therapies for rare and severe diseases that can improve the lives of patients and their families.

What is the Amicus Therapeutics dividend?

Amicus Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Amicus Therapeutics pay dividends?

The dividend cannot currently be calculated for Amicus Therapeutics or the company does not pay out a dividend.

What is the Amicus Therapeutics ISIN?

The ISIN of Amicus Therapeutics is US03152W1099.

What is the Amicus Therapeutics WKN?

The WKN of Amicus Therapeutics is A0MSMZ.

What is the Amicus Therapeutics ticker?

The ticker of Amicus Therapeutics is FOLD.

How much dividend does Amicus Therapeutics pay?

Over the past 12 months, Amicus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amicus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Amicus Therapeutics?

The current dividend yield of Amicus Therapeutics is .

When does Amicus Therapeutics pay dividends?

Amicus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amicus Therapeutics?

Amicus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Amicus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amicus Therapeutics located?

Amicus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amicus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amicus Therapeutics from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Amicus Therapeutics pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Amicus Therapeutics in the year 2023?

In the year 2023, Amicus Therapeutics distributed 0 USD as dividends.

In which currency does Amicus Therapeutics pay out the dividend?

The dividends of Amicus Therapeutics are distributed in USD.

All fundamentals about Amicus Therapeutics

Our stock analysis for Amicus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amicus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.